A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)
Latest Information Update: 08 May 2025
At a glance
- Drugs Zenocutuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Liver metastases; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
- Focus First in man; Registrational; Therapeutic Use
- Acronyms eNRGy
- Sponsors Merus
Most Recent Events
- 05 Feb 2025 According to a Merus media release,the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial (n=204) for Bizengri (zenocutuzumab), for adults with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor NRG1 gene fusion who have disease progression on or after prior systemic therapy.
- 05 Feb 2025 According to partner therapeutics media release, the New England Journal of Medicine (NEJM) published results of the 204-patient, global, multicenter, single-arm, Phase 2 clinical trial of zenocutuzumab-zbco (BIZENGRI)
- 05 Feb 2025 Results presented in the partner therapeutics media release.